Active Cancer Brain & Nervous System
Minimising side effects of Anaplastic Lymphoma Kinase (ALK) inhibitors for neuroblastoma by elimination of off-target activity
About this grant
This summary is based on the grant title only — the full abstract was not available.
Research project funded by MRF at Institute of Cancer Research.
View the original record at the funder ↗
Researchers
Elizabeth Tucker (EPMC Awardee)
Related Research
Grants with similar aims, by meaning.
Therapeutic Targeting of ALK in Neuroblastoma
Targeting the ALK-F1174L tyrosine-kinase mutation in treatment refractory neuroblastoma.
An investigation into the treatment of neuroblastoma with mutations of Anaplastic Lymphoma Kinase (ALK), using LDK378 and LEE011 combination therapy targeting ALK and Cyclin-dependent Kinase (CDK) 4/6, in a preclinical transgenic neuroblastoma model
Phase I study of Lorlatinib (PF-06463922), an oral small molecule inhibitor of ALK/ROS1, for patients with ALK-driven relapsed or refractory neuroblastoma
Improved Treatment of Childhood Neuroblastoma - Targeting the Oncogene Drivers MYCN and ALK, and Identification of Therapy Resistance Mechanisms
Original classification
Impact of Cancer and Cancer Care on Human Biology and Health 2025Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research. Is something wrong? Let us know